Scientists of three leading medical institutions in the country have identified another unique therapeutic property of the domestic biotech drug. FarGALS is effective against pathogens of hepatitis B and C.
FarGALS, developed by local pharmacists, has been represented in the drugs’ market for about five years. It has been used as an antiseptic and wound-healing drug with broad antimicrobial action. It is active against gram-positive and gram-negative, aerobic and anaerobic, spore-forming and nonspore-forming bacteria. It helps to improve the blood supply to the affected area.
Despite the fact that the drug is widely used in clinics in the country, it is very interesting for scientists because many of its healing properties are not fully discovered. Thus, specialists of the Scientific Research Institute of Epidemiology, Microbiology and Infectious Diseases, the Republican Specialized Surgery Center of Vahidov, Institute of Virology completed studies that have shown antiviral activity of this drug against pathogens Hepatitis B and C.
The results of these studies were presented in the II Congress of infectiologists of Uzbekistan ‘Priority areas for treatment and prevention of infectious diseases’, which took place in Tashkent.
The results indicate the presence of a specific antiviral activity of FarGALS against hepatitis B and C. However, the results require additional evidence, according to experts. Investigations are continuing.